Bifidobacterium breve

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Bifidobacterium breve is a Gram-positive, non-spore-forming, anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 23 gut microbiome compilation studies or metastudies. Bifidobacterium breve is often a widespread coloniser of gut. (Bahaka1993; Scardovi1971)



  • This organism has been recovered from human faeces and clinical sources (blood, infection - CCUG). The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread (notes: opportunistic in immunocompromised patients). Is a rare opportunistic pathogen. Is a known gut commensal. Robust growth can have positive consequences for gut health.
    • QUIRKS
  • Found in human breast milk (Jeurink2013).
    • GENERAL CHARACTERISTICS (Bahaka1993); (Scardovi1971);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; mucin;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; fucose; galactose; glucose; ribose; amygdalin; glycogen; starch; lactose; maltose; raffinose; sucrose; D-turanose; mannitol; sorbitol; arbutin; α-methyl glucoside; N-Ac glucosamine; salicin;
  • ⥅
  • Substrates assimilated or utilised:
  • melibiose; mucin;
  • Active enzymes:
  • α-galactosidase; β-galactosidase; α-glucosidase; β-glucosidase; Leu arylamidase; Phe arylamidase;
    • SPECIAL FEATURES (Bahaka1993); (Scardovi1971);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate; lactate;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Kheadr2007); (Matteuzzi1983); (Moubareck2005); (Goldstein2013); (Goldstein2013a); (Citron2012a); (Citron2003); (Goldstein2000a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; cloxacillin; imipenem; oxacillin; penicillin G; piperacillin; piperacillin-tazobactam; ticarcillin; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefotetan; cefoxitin; ceftizoxime; cephalothin;
  • Macrolides:
  • erythromycin; fidaxomicin; pristinamycin; quinupristin-dalfopristin; spiramycin; telithromycin;
  • Tetracyclines:
  • minocycline;
  • Quinolines:
  • gatifloxacin; ofloxacin;
  • nalidixic-acid;
  • Aminoglycosides:
  • gentamicin; kanamycin; neomycin; streptomycin;
  • Polypep/ketides:
  • bacitracin; nisin A; rifampicin;
  • Heterocycles:
  • chloramphenicol; nitrofurantoin;
  • metronidazole;
  • Vancomycins:
  • vancomycin; teicoplanin;
  • Miscellaneous antibiotics:
  • clindamycin; daptomycin; linezolid; pristinamycin; telithromycin;
  • polymyxin B;

  • N/A

  • Bifidobacteria are a common component of the microbiota of the gastrointestinal tract (GIT) of a broad range of hosts, and their presence is associated with a positive health status of the gut. However, little is known about the precise molecular mechanisms that explain these probiotic effects. [PMID: 24581150] Bifidobacteria are a common component of the microbiota of the gastrointestinal tract (GIT) of a broad range of hosts, and their presence is associated with a positive health status of the gut. However, little is known about the precise molecular mechanisms that explain these probiotic effects. This organism is a frequently encountered component of the (adult and infant) human gut microbiota, but can also be isolated from human milk and vagina. [PMID: 24581150] This proteome is redundant to UP000232467. No characterization/functional information was found on the strain. 

  • Reuter, G. (1963). Comparative studies on the bifidus flora in the feces of infants and adults. With a contribution to classification and nomenclature of bifidus strains. Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale, 191, 486–507.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Bifidobacteriales Family:  Bifidobacteriaceae Genus:  Bifidobacterium Gram stain:  + O2 Relation.:  anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:   Positive
    Source:  human faeces and clinical sources (blood, infection - CCUG)
    		Aesculin:  + Urea:  neg Gelatin:  neg Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    D-Arabinose:  vr L-Arabinose:  neg Fructose:  + Fucose:  + D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  vr Rhamnose:  neg Ribose:  + Sorbose:  neg D-Tagatose:  neg Xylose:  neg L-Xylose:  neg Cellubiose:  vr Gentiobiose:  vr Lactose:  + Maltose:  + Melezitose:  neg Sucrose:  + Trehalose:  neg Turanose:  + Amygdalin:  + Dextrin:  neg Glycogen:  + Inulin:  neg Starch:  + Pectin:  neg Xylan:  neg Adonitol:  neg D-Arabitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  + Sorbitol:  + Xylitol:  vr Arbutin:  + Gluconate:  neg 2-Ketogluconate:  neg 5-Ketogluconate:  neg Me-α-D-Glc:  + Me-α-D-Mann:  neg Me-Xyloside:  neg NAc-α-GA:  + Salicin:  +
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  neg Urease:  neg α-Fucosidase:  neg α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  + β-Glucuronidase:  neg β-Mannosidase:  neg ArgDH:  neg GluDC:  neg AlanineAA:  vr AlaPheProAA:  vr GluGluAA:  neg GlyAA:  vr LeuAA:  + LeuGlyAA:  vr PyrrolidAA:  neg PheAA:  + AlkalineP:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  + Lactate:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (≤0.06-1)
    Augmentin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.015-2)
    ampicillin:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.06–1)
    amp-sulb:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.06–1)
    cloxacillin:  Sens
    oxacillin:  S(vr)
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03-1)
    piperacillin:  Sens
    piper-taz:  S(MIC50): 0.06, MIC90: 0.5, RNG: (≤0.03-1)
    ticarcillin:  Sens
    tica-clav:  S(MIC50): 0.06, MIC90: 2, RNG: (0.06–4)
    imipenem:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.015–2)
    cefalexin:  Var(MIC50): 1, MIC90: >32, RNG: (0.25->32)
    cefotaxime:  RNG: (8)
    cefotetan:  S(vr)
    cefoxitin:  S(MIC50): 2, MIC90: 8, RNG: (0.5–32)
    ceftizoxime:  S(4)
    cephalothin:  S(vr)
    gentamicin:  R(MIC50): 200, MIC90: >500, RNG: (30->500)
    kanamycin:  R(>600)
    neomycin:  R(150-500)
    streptomycin:  R(30-1500)
    azithromycin:  Var(MIC50): 0.06, MIC90: 8, RNG: (≤0.03->32)
    erythromycin:  S(MIC50): ≤0.03, MIC90: 2, RNG: (≤0.03-16)
    fidaxomicin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.03–0.25)
    pristinamycin:  Sens
    quin-dalf:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125-0.5)
    spiramycin:  Sens
    telithromycin:  S(MIC50): ≤0.002, MIC90: ≤0.002, RNG: (≤0.002-0.06)
    linezolid:  S(MIC50): 1, MIC90: 1, RNG: (1)
    ciprofloxacin:  Var(MIC50): 1, MIC90: >8, RNG: (≤0.5->8)
    gatifloxacin:  S(MIC50): 1, MIC90: 2, RNG: (0.25-2)
    levofloxacin:  Var(MIC50): 0.5, MIC90: 8, RNG: (0.25-8)
    moxifloxacin:  Var(MIC50): 1, MIC90: 8, RNG: (0.06–16)
    nalidixic-acid:  R(>200)
    ofloxacin:  Sens
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    minocycline:  Sens
    tetracycline:  Var(MIC50): 1, MIC90: 16, RNG: (0.125-32)
    teicoplanin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125–0.5)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-1)
    bacitracin:  S(MIC50): 0.16, MIC90: 0.61, RNG: (0.05-1.5)
    nisin_A:  Sens
    rifampicin:  Sens
    chloramphenicol:  S(MIC50): <1, MIC90: 2.6, RNG: (1-4)
    metronidazole:  R(MIC50): 32, MIC90: >32, RNG: (0.125->32)
    nitrofurantoin:  S(MIC50): 16, MIC90: 19, RNG: (10-20)
    clindamycin:  S(MIC50): ≤0.03, MIC90: 0.5, RNG: (≤0.03->32)
    lincomycin:  Var(MIC50): 1, MIC90: 5.8, RNG: (0.10-15)
    daptomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (≤0.03-1)
    polymyxin_B:  R(>700)

    References

    SPECIFIC REFERENCES FOR BIFIDOBACTERIUM BREVE
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Bahaka1993 - Phenotypic and genomic analyses of human strains belonging or related to Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium breve.
  • Kheadr2007 - Antibiotic Susceptibility Profile of Bifidobacteria as Affected by Oxgall, Acid, and Hydrogen Peroxide Stress.
  • Matteuzzi1983 - Antimicrobial susceptibility of Bifidobacterium.
  • Moubareck2005 - Antimicrobial susceptibility of bifidobacteria.
  • Scardovi1971 - Deoxyribonucleic Acid Homology Relationships Among Species of the Genus Bifidobacterium
  • Mitsuoka1990 - Bifidobacteria and their role in human health.
  • Salyers1977 - Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon
  • Bode2012 - Human milk oligosaccharides: every baby needs a sugar mama
  • Gao2020 - Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Gryp2020 - Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients
  • Hevia2016 - Allergic Patients with Long-Term Asthma Display Low Levels of Bifidobacterium adolescentis
  • Scanlan2012 - Gut dysbiosis in cystic fibrosis
  • Tarallo2019 - Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • Citron2012a - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR BIFIDOBACTERIUM BREVE
  • Almeida2019 - A new genomic blueprint of the human gut microbiota.
  • Aujoulat2014 - Temporal dynamics of the very premature infant gut dominant microbiota.
  • Benno1984 - The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Favier2002 - Molecular monitoring of succession of bacterial communities in human neonates.
  • Finegold1974 - Effect of diet on human fecal flora: comparison of Japanese and American diets
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • King2019 - Baseline human gut microbiota profile in healthy people and standard reporting template.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • MacFarlane2004 - Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • Nielsen2014 - MetaHIT Consortium. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes.
  • Pandey2012 - Comparative analysis of fecal microflora of healthy full-term Indian infants born with different methods of delivery (vaginal vs cesarean): Acinetobacter sp. prevalence in vaginally born infants.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Tyakht2013 - Human gut microbiota community structures in urban and rural populations in Russia.
  • Wang2020a - Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR BIFIDOBACTERIUM BREVE
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
    • Added: February 08, 2021